Value Health

• 

  Publication Venue For

  • Accounting for Preference Heterogeneity in Discrete-Choice Experiments: An ISPOR Special Interest Group Report..  25:685-694. 2022
  • Cost and Quality of Life Outcomes of the STepped Exercise Program for Patients With Knee OsteoArthritis Trial..  25:614-621. 2022
  • Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma..  25:582-594. 2022
  • Quantifying Value of Hope..  24:1511-1519. 2021
  • Rasch Analysis of Patient- and Parent-Reported Outcome Measures in the International Consortium for Health Outcomes Measurement Standard Set for Cleft Lip and Palate..  24:404-412. 2021
  • Willingness to Accept Trade-Offs Among COVID-19 Cases, Social-Distancing Restrictions, and Economic Impact: A Nationwide US Study..  23:1438-1443. 2020
  • Bias in Mean Survival From Fitting Cure Models With Limited Follow-Up..  23:1034-1039. 2020
  • Heterogeneous Patient Preferences for Modern Antiretroviral Therapy: Results of a Discrete Choice Experiment..  23:851-861. 2020
  • Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report..  23:409-415. 2020
  • Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention..  23:61-73. 2020
  • Something Is Better Than Nothing: The Value of Active Intervention in Stated Preferences for Treatments to Delay Onset of Alzheimer's Disease Symptoms..  22:1063-1069. 2019
  • A Beginner's Guide to Understanding Curative Therapies..  22:619-620. 2019
  • Comparing the Noncomparable: The Need for Equivalence Measures That Make Sense in Health-Economic Evaluations..  22:684-692. 2019
  • Novel Approaches to Value Assessment Beyond the Cost-Effectiveness Framework..  22:S18-S23. 2019
  • PROMIS® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains..  22:537-544. 2019
  • The Internal Validity of Discrete Choice Experiment Data: A Testing Tool for Quantitative Assessments..  22:157-160. 2019
  • Psychometric Evaluation of the Patient's Knee Implant Performance Questionnaire..  21:1305-1312. 2018
  • Researchers, Patients, and Stakeholders Evaluating Comparative-Effectiveness Research: A Mixed-Methods Study of the PCORI Reviewer Experience..  21:1161-1167. 2018
  • Unique Review Criteria and Patient and Stakeholder Reviewers: Analysis of PCORI's Approach to Research Funding..  21:1152-1160. 2018
  • Be Careful What You Ask For: Effects of Benefit Descriptions on Diabetes Patients' Benefit-Risk Tradeoff Preferences..  20:670-678. 2017
  • Advancing Value Assessment in the United States: A Multistakeholder Perspective..  20:299-307. 2017
  • Estimating Preferences for Complex Health Technologies: Lessons Learned and Implications for Personalized Medicine..  20:32-39. 2017
  • Psychometric Properties of the Four-Item Morisky Green Levine Medication Adherence Scale among Atherosclerosis Risk in Communities (ARIC) Study Participants..  19:996-1001. 2016
  • International Experiences in Quantitative Benefit-Risk Analysis to Support Regulatory Decisions..  19:727-729. 2016
  • Patient Preferences in Regulatory Benefit-Risk Assessments: A US Perspective..  19:741-745. 2016
  • A PROMIS Measure of Neuropathic Pain Quality..  19:623-630. 2016
  • Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force..  19:300-315. 2016
  • Responsiveness to Change in PROMIS(®) Measures among Children with Asthma: A Report from the PROMIS(®) Pediatric Asthma Study..  19:192-201. 2016
  • Do You Want to Hear the Bad News? The Value of Diagnostic Tests for Alzheimer's Disease..  19:66-74. 2016
  • The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?.  19:88-98. 2016
  • A Vision "Bolt-On" Item Could Increase the Discriminatory Power of the EQ-5D Index Score..  18:1037-1042. 2015
  • Methods for Developing Patient-Reported Outcome-Based Performance Measures (PRO-PMs)..  18:493-504. 2015
  • The Value Adults Place on Child Health and Functional Status..  18:449-456. 2015
  • Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report..  18:161-172. 2015
  • Pediatricians' preferences for infant meningococcal vaccination..  18:67-77. 2015
  • Physicians' preferences for bone metastases drug therapy in the United States..  18:78-83. 2015
  • Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes..  17:854-862. 2014
  • US valuation of health outcomes measured using the PROMIS-29..  17:846-853. 2014
  • Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening..  17:838-845. 2014
  • Effect of Oral Nutritional Supplements On Hospital Outcomes in Patients Aged 65+ With Congestive Heart Failure..  17:A503. 2014
  • Patients' Preferences for Bone Metastases Treatments in Turkey..  17:A648. 2014
  • Physicians' Preferences for Bone Metastases Treatments in Turkey..  17:A570. 2014
  • The Value of Diagnostic Tests for Alzheimer's Disease: Discrete-Choice Experiment and Contingent-Valuation..  17:A402. 2014
  • Understanding Medication Adherence Using Stated-Preference Data..  17:A492-A493. 2014
  • A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer..  17:545-554. 2014
  • Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment..  16:385-393. 2013
  • Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force..  16:3-13. 2013
  • A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs..  15:1014-1021. 2012
  • PRM145 A Maximum Likelihood Simulation Technique for Estimating Adverse Event Rates From Published Trials..  15:A487. 2012
  • Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response..  15:876-886. 2012
  • Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States..  15:632-638. 2012
  • Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial..  15:277-283. 2012
  • Assuring the patient centeredness of patient-reported outcomes: content validity in medical product development and comparative effectiveness research..  14:965-966. 2011
  • Development, reliability, and validity of a new Preference and Satisfaction Questionnaire..  14:1109-1116. 2011
  • When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia..  14:1055-1056. 2011
  • Evaluating patient-reported outcome measurement comparability between paper and alternate versions, using the lung function questionnaire as an example..  14:712-720. 2011
  • Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force..  14:403-413. 2011
  • Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis..  14:483-491. 2011
  • Utility scores and treatment preferences for clinical early-stage cervical cancer..  14:582-586. 2011
  • The CHD challenge: comparing four cost-effectiveness models..  14:53-60. 2011
  • What do international pharmacoeconomic guidelines say about economic data transferability?.  13:1028-1037. 2010
  • Quantifying women's stated benefit-risk trade-off preferences for IBS treatment outcomes..  13:418-423. 2010
  • Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome..  13:411-417. 2010
  • Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli managed healthcare organization.  381-387. 2010
  • Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer..  12:637-640. 2009
  • Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States..  12:666-673. 2009
  • Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy..  12:217-225. 2009
  • Editorial: Moving the QALY forward or just stuck in traffic?.  12 Suppl 1:S38-S39. 2009
  • Using conjoint analysis to estimate healthy-year equivalents for acute conditions: an application to vasomotor symptoms..  12:146-152. 2009
  • Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation..  11:1022-1032. 2008
  • Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy..  11:172-179. 2008
  • Development, validation, and application of a microsimulation model to predict stroke and mortality in medically managed asymptomatic patients with significant carotid artery stenosis..  10:489-497. 2007
  • Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis. 2022
  • What is sufficient evidence for the reliability and validity of patient-reported outcome measures? 2007